Gross Margin % is calculated as gross profit divided by its revenue. Ionis Pharmaceuticals's Gross Profit for the
three
months ended in Dec. 2023 was $321.4 Mil. Ionis Pharmaceuticals's Revenue for the
three
months ended in Dec. 2023 was $324.5 Mil. Therefore, Ionis Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 99.06%.
The historical rank and industry rank for Ionis Pharmaceuticals's Gross Margin % or its related term are showing as below:
IONS'
s Gross Margin % Range Over the Past 10 Years
Min: 97.6 Med: 98.75 Max: 99.7
Current: 98.84
During the past 13 years, the highestGross Margin % of Ionis Pharmaceuticals was 99.70%. The lowest was 97.60%. And the median was 98.75%.
IONS's Gross Margin % is ranked better than 97.14% of 735
companies
in the Biotechnology industry
Industry Median: 59.86
vs IONS: 98.84
Ionis Pharmaceuticals had a gross margin of 99.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Ionis Pharmaceuticals was -0.30% per year.
Ionis Pharmaceuticals Gross Margin % Historical Data
The historical data trend for Ionis Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ionis Pharmaceuticals's Gross Margin %
For the Biotechnology subindustry, Ionis Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ionis Pharmaceuticals had a gross margin of 99.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ionis Pharmaceuticals Gross Margin % Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IONS has been successfully added to your 